Virtual Library

Start Your Search

Yuanyuan Liu



Author of

  • +

    EP1.14 - Targeted Therapy (ID 204)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Targeted Therapy
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.14-20 - EGFR T790M Mutated Cells Are Not a New Emerging Sub-Clonal Population in Lung Adenocarcinoma After the Treatment of Targeted Therapy (Now Available) (ID 1443)

      08:00 - 18:00  |  Author(s): Yuanyuan Liu

      • Abstract
      • Slides

      Background

      EGFR TKI targeted therapy has improved prognosis for lung adenocarcinoma patients. Almost all patients inevitably develop acquired resistance to these agents, mainly through EGFR T790M mutation. Lung adenocarcinoma patients retained the sensitive mutation and simultaneously acquired the T790M resistance mutation. Whether the acquired T790M mutation is in a newly formed cell groups, or they co-exist with the sensitive mutation in the same cell remained unknown.

      Method

      RNA in situ hybridization (ISH) methods were employed to examine EGFR T790M and L858R mutations. EGFR L858R mtation probe was labelled with blue color and T790M was labelled with red color. EGFR mutations were also assessed using PCR methods.

      Result

      Results of RNA ISH and PCR analyses were identical in the majority of examined tissues. We observed that the T790M and L858R mutations co-expressed in the same cell in both the primary and acquired resistance tissue samples. For the two cases with tissues available following third generation TKI therapy, we observed that the T790M mutation disappeared in the repeated biopsy specimen.

      6.jpg

      Conclusion

      The EGFR sensitive mutation is a trunk and drive mutation, while T790M is a gatekeeper mutation that can appear or disappear under the pressure of TKI therapy. EGFR T790M mutation isn't a new emerging cell clone and co-existed with the sensitive mutation in the same cell.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    MA18 - Advances in Diagnosis of Common Types of NSCLC (ID 145)

    • Event: WCLC 2019
    • Type: Mini Oral Session
    • Track: Pathology
    • Presentations: 1
    • Now Available
    • +

      MA18.11 - SNAI2 Is the Most Highly Differential Expressed Genes Between the Adenomatous and Squamous Components of Lung Adenosquamous Cell Carcinoma (Now Available) (ID 1357)

      11:30 - 13:00  |  Author(s): Yuanyuan Liu

      • Abstract
      • Presentation
      • Slides

      Background

      Lung adenosquamous cell carcinoma is a hybrid tumor with adenomatous and squamous components in one tumor, it has the worst prognosis among the non small cell lung cancer.

      Our previous work has prooved that lung adenosquamous cell carcinoma has a similar EGFR mutation rate as lung adenocarcinoma which is 51.79% in 56 patients. Further squencing results showed that the majority of adnematous and squamous components had identical mutation type (34/37). EGFR mutated adenosquamous cell carcinoma patients are prone to be young, female and non-smokers, which are similar with the clinical charateristics of lung adenocarcinoma.

      Besides the corcodant mutation profile between the two different components of lung adenosquamous cell carcinoma, if there are any differentail expressed genes remained mysterious. our study will addressed this question.

      图3.jpg

      Method

      NanoString nCounter technology was employed in our study. it has been increasingly used for mRNA or miRNA differential expression studies because of its advantages of feasibility in formalin fixed paraffin embedded samples. We compared the differential expressed gene profiles between the paired matched adenomatous and squamous components in 24 adenosquamous cancer tissues.

      Result

      SNAI2 is found to be the most differential expressed genes between the two components in lung adenosquamous cell carcinoma. It is higher expressed in squamous component compared with the adenomatous component. SNAI2 is a member of epithelial to mesenchymal transition signalling pathway. Other research results showed that SNAI2 played a pivotal role in controlling the epithelial and mesenchymal transdifferentiation, stem cell property of cancer cell, and the metastasis ability.

      snai2.jpg

      Conclusion

      Our preliminary results showed that SNAI2 which is a member of EMT signalling pathway is highly expressed in the squamous component compared with the adenomatous component of lung ASC. It may contribute to the phenotype transdifferentiated and invasion of lung ASC.

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.